Coya Therapeutics’ (COYA) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a research report released on Monday morning,Benzinga reports. D. Boral Capital currently has a $15.00 target price on the stock.

COYA has been the topic of a number of other reports. Chardan Capital reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a research note on Thursday, February 6th. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Coya Therapeutics in a report on Monday, November 11th.

Coya Therapeutics Trading Down 1.0 %

Coya Therapeutics stock opened at $6.63 on Monday. Coya Therapeutics has a 1-year low of $4.75 and a 1-year high of $10.69. The firm has a market capitalization of $110.77 million, a price-to-earnings ratio of -10.20 and a beta of 0.31. The firm’s fifty day moving average price is $6.25 and its two-hundred day moving average price is $6.46.

Institutional Trading of Coya Therapeutics

A number of large investors have recently added to or reduced their stakes in COYA. Tower Research Capital LLC TRC increased its holdings in Coya Therapeutics by 1,005.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company’s stock worth $30,000 after buying an additional 4,777 shares during the last quarter. XTX Topco Ltd purchased a new stake in Coya Therapeutics during the fourth quarter worth about $59,000. Jane Street Group LLC purchased a new stake in Coya Therapeutics during the fourth quarter worth about $74,000. Northern Trust Corp boosted its position in Coya Therapeutics by 12.2% during the fourth quarter. Northern Trust Corp now owns 28,549 shares of the company’s stock worth $164,000 after purchasing an additional 3,099 shares during the period. Finally, Newbridge Financial Services Group Inc. bought a new position in Coya Therapeutics during the fourth quarter worth about $401,000. Hedge funds and other institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.